Health Condition 1: K296- Other gastritis
Conditions
Interventions
Intervention1: Triple drug therapy: Pylokit from Cipla Ltd. [containing tablets of Tinidazole (500mg), Clarithromycin: (250mg), Lansoprazole:(30mg)]
One tablet of each will be given to the patients tw
Sponsors
Department Of Jarahat AKTC AMU
Eligibility
Inclusion criteria
Inclusion criteria: Endoscopic Diagnosis: H. pylori induced gastritis patients diagnosed on endoscopy using Rapidurease test (RUT) kit and histopathology. Patient given written consent.
Exclusion criteria
Exclusion criteria: Patients of age below 14years. Pregnant and lactating mothers. Patient sensitive to any of the test or standard drugs included in the study will be excluded along with appropriate treatment, as and when required. Severe Comorbidities: Participants with severe comorbidities such as advanced malignancies, severe cardiac, hepatic, renal diseases,Tuberculosis, Acute or Chronic Ulcerative colitis, Cohn s disease, Positive case of Venereal disease, HIV and HBsAg in including Diabetes. Allergies and Intolerances: Known allergies or intolerances to medications used for the treatment of upper GI inflammatory conditions or H. pylori eradication. Already taken PPI [H.PYLORI] Kit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endoscopic findings H. Pylori RUT kit Timepoint: At the time of First visit and than after three months of the treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dyspepsia Pain Abdomen Heart burn Melena Dysphagia Anemia Indigestion Belching Nausea/ Vomiting FlatulenceTimepoint: 2 weeks 1 month 3 month | — |
Countries
India
Contacts
Public ContactNida Saeed
Aligarh Muslim University
Outcome results
None listed